PhD Aleksandar Dekanski PhD Branka Dražić

JSCS Journal Manager Faculty of Pharmacy

**Manuscript title: " Synthesis and characterization of copper (II) octaazamacrocyclic complexes with glycine derivatives. *In vitro* antiproliferative and antimicrobial evaluation of Cu(II) and Co(II) analogous"**

Dear Aleksandar Dekanski,

Thanks for the helpful comments and suggestions. Accordingly, we have revised the manuscript and all corrections are highlighted in the text of the manuscript.

Responsee to the comments

1. Tables III, IV, V and Fig. 2 were corrected according to your comments.
2. We removed underline in the whole manuscript.
3. We re-formatted the all references (font and some other highlighted corection).

Some sentences have been modified:

Page10: “TABLE II. Antimicrobial activity of the tested complexes and referent antibiotics in microdilution test.” was replaced with : “TABLE II. Antimicrobial activity of the tested complexes (**1**-**4**) and referent antibiotics expressed as MIC, determined by the brouth microdilution methods.”

Page11: “TABLE III. Minimal bactericidal concentration (MBC) and MBC/MIC ratio for tested complexes” was replaced with : “TABLE III. Minimal bactericidal concentration (MBC) and MBC/MIC ratio for tested complexes **1-4.**”

Page11: “TABLE IV. IC50 (µM) for the 72 h of action of investigated compounds, ligands and cisplatin on the tested cells determined by MTT test.” was replaced with : “TABLE IV. IC50 (µM) for the 72 h of action of investigated complexes **1**-**4**, ligands and cisplatin on the tested cell lines determined by MTT test.”

Page12: “Fig 2. Dose-response curves for the cytotoxicity of **1**-**4** toward HeLa, K562, MDA-MB-453, and MRC-5 cells.” was replaced with : “Fig 2. Dose-response curves for the cytotoxicity of complexes **1**-**4** toward HeLa, K562, MDA-MB-453, and MRC-5 cells.”

We also want changes:

1. Manuscript title: " Synthesis and characterization of copper (II) octaazamacrocyclic complexes with glycine derivatives. In vitro antiproliferative and antimicrobial evaluation of Cu(II) and Co(II) analogous"
2. Abstract: Two new complexes with general formula [Cu2(L)tpmc](ClO4)3·nH2O (tpmc = *N,N′,N′′,N′′′*-tetrakis(2-pyridylmethyl)-1,4,8,11-tetraazacyclotetradecane, L = *N-*methylglycine, n=3; L=*N,N*-dimethylglycine, n =2) were isolated and their composition, some physical and chemical properties and geometries were proposed by elemental analysis (C, H, N), conductometric and magnetic measurements and spectroscopic data (UV-Vis,FTIR). It is evident that complexes are binuclear and proposed an *exo* coordination mode of macrocyclic ligand in the boat conformation. The co-ligands are coordinated as a bridge using both oxygen atoms of the OCO– group. The cytotoxic activity of Cu(II) complexes as well as their Co(II) analogs, the starting ligands and the free salts were tested against human cervix adenocarcinoma cell line (HeLa), human chronic myelogenous leukemia cells (K562), human breast cancer cell line (MDA-MB-453), and a non-cancerous cell line, human embryonic lung fibroblast (MRC-5). The IC50 values for Cu(II) complexes were from 21.60 ± 0.04 to 66.1±0.8, and for the Co(II) analogs were within the range from 8.8 ± 0.74 to 15.40 ± 1.52. All four complexes were tested for antimicrobial activity against *Staphylococcus aureus*, *Bacillus subtilis*, *Escherichia coli* and the yeast *Candida albicans*.
3. For autors Branka Dražić and Slađana Tanasković afilation: Faculty of Pharmacy, University of Belgrade Vojvode Stepe 450 11000 Belgrade, Serbia;

We hope that our paper is now suitable for publication as original scientific paper in Journal of the Serbian Chemical Society.

August 21th, 2019. Sincerely yours,

Branka Dražić